2.34

20.62% 0.40

Pacific Biosciences Of California Inc (PACB)

Overview News Price History Option Chain Financials Why PACB Down? Discussions Forecast

Pacific Biosciences Of California Inc stock is traded at $2.34, with a volume of 22.62M. It is up +20.62% in the last 24 hours and up +82.81% over the past month. Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Previous Close:

$1.94

Open:

$2.065

24h Volume:

22.62M

Relative Volume:

2.92

Market Cap:

$702.87M

Revenue:

$188.87M

Net Income/Loss:

$-400.38M

P/E Ratio:

-1.56

EPS:

-1.5

Net Cash Flow:

$-260.90M

1W Performance:

+15.84%

1M Performance:

+82.81%

6M Performance:

+110.81%

1Y Performance:

+7.83%

1-Day Range:

$2.05

$2.37

1-Week Range:

$1.91

$2.37

52-Week Range:

$0.8511

$2.72

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Name

Pacific Biosciences Of California Inc

Sector

Healthcare (1135)

Industry

Medical Devices (144)

Phone

650-521-8000

Address

1305 O'BRIEN DRIVE, MENLO PARK, CA

Employee

575

Twitter

@pacbio

Next Earnings Date

2024-11-07

Latest SEC Filings

PACB's Discussions on Twitter

Compare PACB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PACB Pacific Biosciences Of California Inc	2.34	582.72M	188.87M	-400.38M	-260.90M	-1.50
ABT Abbott Laboratories	123.62	216.79B	43.84B	13.90B	6.92B	7.9725
BSX Boston Scientific Corp	100.72	149.02B	19.35B	2.78B	3.49B	1.8696
SYK Stryker Corp	356.24	141.06B	23.82B	2.92B	4.02B	7.5574
MDT Medtronic Plc	90.70	116.68B	34.20B	4.69B	5.30B	3.6218
EW Edwards Lifesciences Corp	82.45	49.01B	5.69B	1.41B	577.90M	1.8485

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Downgrade	UBS	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Buy
Apr-22-24	Downgrade	JP Morgan	Overweight → Neutral
Apr-18-24	Downgrade	Goldman	Buy → Neutral
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-14-23	Initiated	Stephens	Overweight
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-17-23	Upgrade	UBS	Neutral → Buy
Oct-31-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Jul-05-23	Resumed	JP Morgan	Overweight
Jun-30-23	Initiated	Goldman	Buy
May-10-23	Initiated	Barclays	Equal Weight
Mar-31-23	Upgrade	TD Cowen	Market Perform → Outperform
Feb-02-23	Initiated	UBS	Neutral
Jan-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-21-22	Resumed	Cantor Fitzgerald	Overweight
Jan-06-22	Resumed	Piper Sandler	Neutral
Oct-15-21	Resumed	Cowen	Market Perform
Sep-27-21	Initiated	Canaccord Genuity	Buy
Feb-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Nov-03-20	Downgrade	Piper Sandler	Overweight → Neutral
Oct-02-20	Upgrade	JP Morgan	Neutral → Overweight
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight
Mar-09-20	Resumed	Cantor Fitzgerald	Overweight
Oct-15-19	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-02-19	Downgrade	Stephens	Overweight → Equal-Weight
Oct-19-18	Initiated	Cowen	Outperform
Nov-03-17	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-28-17	Downgrade	CL King	Buy → Neutral
Nov-03-16	Reiterated	Cantor Fitzgerald	Buy
Jun-27-16	Initiated	CL King	Buy
Apr-15-16	Initiated	First Analysis Sec	Overweight
Feb-04-16	Downgrade	Piper Jaffray	Overweight → Neutral
Jan-04-16	Reiterated	Cantor Fitzgerald	Buy
Oct-23-15	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-27-15	Initiated	Cantor Fitzgerald	Buy
Feb-04-15	Reiterated	Maxim Group	Buy
Sep-26-13	Reiterated	Maxim Group	Buy
Jan-14-13	Reiterated	Maxim Group	Buy

View All

Pacific Biosciences Of California Inc Stock (PACB) Latest News

05:32 AM

Analyzing recovery setups for Pacific Biosciences of California Inc. investorsMarket Sentiment Review & Growth Focused Stock Pick Reports - newser.com

05:32 AM

03:04 AM

Will Pacific Biosciences of California Inc. continue its uptrendJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com

03:04 AM

02:50 AM

Will Pacific Biosciences of California Inc. stock sustain high P E ratios2025 Growth vs Value & Scalable Portfolio Growth Methods - newser.com

02:50 AM

02:44 AM

Will Pacific Biosciences of California Inc. stock split attract more investorsWeekly Stock Analysis & Daily Stock Trend Reports - newser.com

02:44 AM

01:52 AM

Is Pacific Biosciences of California Inc. stock ready for a breakoutEarnings Risk Report & Long-Term Investment Growth Plans - newser.com

01:52 AM

01:53 AM

Why Pacific Biosciences of California Inc. stock is favored by top institutionsJuly 2025 Selloffs & Safe Entry Point Identification - newser.com

01:53 AM

Nov 01, 2025

Can Pacific Biosciences of California Inc. stock resist market sell offsTrade Ideas & Verified Technical Signals - newser.com

Nov 01, 2025

How to build a custom watchlist for Pacific Biosciences of California Inc.Insider Buying & Safe Capital Allocation Plans - newser.com

Nov 01, 2025

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap UpHere's What Happened - MarketBeat

Nov 01, 2025

Pacific Biosciences of California (NASDAQ:PACB) Shareholders Are up 16% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛

Nov 01, 2025

Carret Asset Management LLC Buys New Holdings in Pacific Biosciences of California, Inc. $PACB - MarketBeat

Nov 01, 2025